Caxton Corporation’s Addex Therapeutics ADXN Stock Holding History

Caxton Corporation’s Portfolio ADXN Stock Details ADXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-13,297	Closed	-$1.35M	–	17
2022 Q1	$1.35M	Hold	13,297	–	–	1.68%	9
2021 Q4	$1.67M	Hold	13,297	–	–	1.37%	13
2021 Q3	$2.4M	Hold	13,297	–	–	1.94%	11
2021 Q2	$2.54M	Hold	13,297	–	–	1.74%	11
2021 Q1	$2.79M	Hold	13,297	–	–	1.81%	11
2020 Q4	$3.56M	Buy	13,297 +12,427	+1,428%	+$3.08M	2.22%	11
2020 Q3	$213K	Sell	870 -1	-0.1%	-$242	0.2%	15
2020 Q2	$152K	Hold	871	–	–	0.16%	15
2020 Q1	$115K	Buy	+871	New	+$152K	0.13%	16

Other funds holding ADXN

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

OMC

Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Caxton Corporation's ADXN Position: Q2 2022 in Review

Caxton Corporation sold out of Addex Therapeutics (ADXN) in Q2 2022, closing a stake of 13,297 shares — an estimated $1.35M sold.

Caxton Corporation first reported a position in ADXN in Q1 2020 and held it in 9 quarters. The position peaked at $3.56M in Q4 2020. 5 funds tracked by Wall St. Rank hold ADXN as of Q2 2022.

Caxton Corporation reported no remaining Addex Therapeutics position as of Q2 2022 after selling out during the quarter.
Caxton Corporation sold 13,297 Addex Therapeutics shares in Q2 2022, an estimated $1.35M.
Caxton Corporation first reported a position in Addex Therapeutics in Q1 2020 and held it in 9 quarters.
Caxton Corporation's Addex Therapeutics position peaked at $3.56M in Q4 2020.
5 funds tracked by Wall St. Rank held Addex Therapeutics as of Q2 2022.

Based on Caxton Corporation's 13F filing for Q2 2022, filed 15 Aug 2022.